Tilray Medical Bolsters Market Leading Position in Europe With Market Authorization in Poland
Polish Ministry of Health Approves Tilray Branded Medical Cannabis for Pharmaceutical Distribution in Addition to Wholesale Approval
LEAMINGTON, Ontario and CANTANHEDE, Portugal, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis division, Tilray Medical, has received approval to commercialize its Tilray branded medical cannabis products in Poland expanding its product offering and distribution across pharmacies in Europe.
Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International Business, said, “I’m extremely proud of our team in Europe for once again expanding our approved authorization for Tilray Medical products across Europe. Tilray will continue to advocate for reasonable patient access to reliable and high-quality medical cannabis in Europe and countries around the world.”
Tilray Medical is a leading international provider of EU-GMP certified medical cannabis products in 21 countries with a comprehensive portfolio of trusted and reliable THC and CBD products each with a unique profile of cannabinoids and terpenes, that have been selected to ensure patients can receive both the highest product quality as well as consistency when it comes to supply of their medicinal cannabis products.
In Poland, Tilray Medical has established multiple partnerships with pharmaceutical companies to distribute both Tilray branded and unbranded medical cannabis products. Patients may obtain prescriptions for medical cannabis in Poland through their preferred medical doctor.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, and Symbios. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first EU-GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 21 countries and across five continents.
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body, and soul while invoking wellbeing. Patients and consumers trust Tilray Brands to deliver a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company’s ability to expand its offering to patients worldwide, including via Tilray Medical. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
For further information:
Media, Tilray Global: email@example.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Boyden Appoints Janne Jakola Partner in Finland3.10.2022 04:00:00 CEST | Press release
Prominent business leader and CEO of Matkahuolto joins Boyden, bringing digital transformation, change leadership and business turnaround expertise to clients worldwide Helsinki, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Boyden, a premier leadership and talent advisory firm with more than 75 offices in over 45 countries, is delighted to welcome prominent business leader Janne Jakola as Partner in Finland effective 1st October 2022. “We at Boyden Finland are delighted to bring such vast technology business and digital services leadership experience to the firm,” commented Erkki Panula, Chairman of Boyden in Finland, and member of the global technology, healthcare & life sciences and fintech practices. “Janne has extensive experience in leading companies and businesses with novel digital services platforms and customer experience, not only in Finland, but in an international context.” Jakola will contribute to Boyden both locally and internationally with C-suite and board assignments as a senior
EMGA completes EUR 9.4M capital raise for Kashf Foundation with financing from BIO3.10.2022 02:00:00 CEST | Press release
LONDON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- The EURO 9.4 million funding facility for Kashf Foundation was originated, structured, and negotiated by Emerging Markets Global Advisory LLP (EMGA), the emerging market investment bank. Speaking on the transaction, Mr Shahzad Iqbal, CFO of Kashf Foundation said, “Kashf Foundation is registered as a Non-Banking Micro Finance Company regulated by the Securities and Exchange Commission of Pakistan. Set up in 1996 as the first specialized microfinance institution of Pakistan it began its operations as a Grameen replicator and since then, Kashf has successfully carved out a distinct and unique niche for itself in the microfinance sector in Pakistan by offering a suite of innovative and transformative products and services to low-income households especially for women. It has a current outreach of over 600,00+ female borrowers across its 360+ branches with a GLP of USD 90+ million.” “Just to share that it has always been a pleasure working with EMGA
FRO - 2022 Annual General Meeting30.9.2022 22:30:00 CEST | Press release
Frontline Ltd. (the “Company”) advises that the 2022 Annual General Meeting of the Shareholders of the Company was held on September 30, 2022 at 08:00 a.m. at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton Bermuda. The audited consolidated financial statements for the Company for the year ended December 31, 2021 were presented to the Meeting. In addition, the following resolutions were passed: To set the maximum number of Directors to be not more than eight. To resolve that vacancies in the number of Directors be designated as casual vacancies and that the Board of Directors be authorised to fill such vacancies as and when it deems fit. To re-elect John Fredriksen as a Director of the Company. To re-elect James O’Shaughnessy as a Director of the Company. To re-elect Ola Lorentzon as a Director of the Company. To re-elect Ole B. Hjertaker as a Director of the Company. To re-elect Steen Jakobsen as a Director of the Company. To re-appoint PricewaterhouseCoopers AS of Oslo,
GOGL – 2022 AGM Results Notification30.9.2022 22:30:00 CEST | Press release
Golden Ocean Group Limited (the “Company”) advises that the 2022 Annual General Meeting of the Shareholders of the Company was held on September 30, 2022 at 08:30 a.m. at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton Bermuda. The audited consolidated financial statements for the Company for the year ended December 31, 2021 were presented to the Meeting. In addition, the following resolutions were passed: To set the maximum number of Directors to be not more than eight. To resolve that vacancies in the number of Directors be designated as casual vacancies and that the Board of Directors be authorized to fill such vacancies as and when it deems fit. To re-elect John Fredriksen as a Director of the Company. To re-elect Ola Lorentzon as a Director of the Company. To re-elect James O’Shaughnessy as a Director of the Company. To re-elect Bjørn Tore Larsen as a Director of the Company. To re-elect Ben Mills as a Director of the Company. To re-appoint PricewaterhouseCoopers AS
Wolters Kluwer acquires Open Access publisher30.9.2022 20:45:00 CEST | Press release
Wolters Kluwer acquires Open Accesspublisher; Expands Breadth of Lippincott Journal Portfolio Waltham, MA, September 30, 2022 – Wolters Kluwer Health announced today that it has signed and completed an agreement to acquire IJS Publishing Group (IJSPG), a UK-based provider of peer-reviewed medical journals supporting scientists and authors. The IJSPG portfolio consists of 10 journal titles, including the International Journal of Surgery (IJS), IJS Case Reports (IJSCR), and Annals of Medicine and Surgery (AMS). IJSPG will become part of Health Learning, Research & Practice (LRP), which offers the Ovid®medical researchsolution, publishes over 300 medical journals and hundreds of medical and nursing books, and produces digital nursing solutions for education and practice. The acquisition expands the breadth and depth of the Lippincott journal portfolio with high impact factor, surgery-related research and strengthens its Open Access position with several well-established journals accessibl